Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 18/2008

01-12-2008 | Review Article

Antidepressants for the Treatment of Chronic Pain

Authors: Bénédicte Verdu, Isabelle Decosterd, Thierry Buclin, Professor Friedrich Stiefel, Alexandre Berney

Published in: Drugs | Issue 18/2008

Login to get access

Abstract

Chronic pain represents one of the most important public health problems and, in addition to classical analgesics, antidepressants are an essential part of the therapeutic strategy. This article reviews available evidence on the efficacy and safety of antidepressants in major chronic pain conditions; namely, neuropathic pain, headaches, low back pain, fibromyalgia, irritable bowel syndrome (IBS) and cancer pain. Studies, reviews and meta-analyses published from 1991 to March 2008 were retrieved through MEDLINE, PsycINFO and the Cochrane database using numerous key words for pain and antidepressants. In summary, evidence supports the use of tricyclic antidepressants in neuropathic pain, headaches, low back pain, fibromyalgia and IBS. The efficacy of the newer serotonin and norepinephrine reuptake inhibitors is less supported by evidence, but can be recommended in neuropathic pain, migraines and fibromyalgia. To date, evidence does not support an analgesic effect of serotonin reuptake inhibitors, but beneficial effects on well-being were reported in several chronic pain conditions. These results are discussed in the light of current insights in the neurobiology of pain, the reciprocal relationship between pain and depression, and future developments in this field of research.
Literature
1.
Bouhassira D. Definition and classification of neuropathic pain [in French]. Presse Med 2008; 37: 311–4PubMedCrossRef
2.
Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain 1999; Suppl. 6: S141–7
3.
Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140: 441–51PubMed
4.
Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 40(18): 1630–5CrossRef
5.
Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555–64PubMedCrossRef
6.
Harris RE, Clauw DJ, Scott DJ, et al. Decreased central muopioid receptor availability in fibromyalgia. J Neurosci 2007; 27: 10000–6PubMedCrossRef
7.
Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003; 48: 1420–9PubMedCrossRef
8.
Banic B, Petersen-Felix S, Andersen OK, et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain 2004; 107: 7–15PubMedCrossRef
9.
10.
Stiefel F, Stagno D. Management of insomnia in patients with chronic pain conditions. CNS Drugs 2004; 18: 285–96PubMedCrossRef
11.
Merskey H, Bogduk N. International Association for the Study of Pain (IASP). Task force on taxonomy: classification of chronic pain. Seattle (WA): IASP Press, 1994
12.
13.
Cummins TR, Sheets PL, Waxman SG. The roles of sodium Channels in nociception: implications for mechanisms of pain. Pain 2007; 131: 243–57PubMedCrossRef
14.
Ignatowski TA, Sud R, Reynolds JL, et al. The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-alpha (TNF). Neuropharmacology 2005; 48: 448–60PubMedCrossRef
15.
Mico JA, Ardid D, Berrocoso E, et al. Antidepressants and pain. Trends Pharmacol Sci 2006; 27: 348–54PubMedCrossRef
16.
Yaron I, Shirazi I, Judovich R, et al. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999; 42: 2561–8PubMedCrossRef
17.
Berta T, Poirot O, Pertin M, et al. Transcriptional and functional profiles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain. Mol Cell Neurosci 2008; 37: 196–208PubMedCrossRef
18.
Pertin M, Ji RR, Berta T, et al. Upregulation of the voltage-gated sodium channel beta2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons. J Neurosci 2005; 25: 10970–80PubMedCrossRef
19.
Brau ME, Dreimann M, Olschewski A, et al. Effect of drugs used for neuropathic pain management on tetrodotoxin-resistant Na(+) currents in rat sensory neurons. Anesthesiology 2001; 94: 137–44PubMedCrossRef
20.
Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289–305PubMedCrossRef
21.
Sindrup SH, Otto M, Finnerup NB, et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96: 399–409PubMedCrossRef
22.
Song JH, Ham SS, Shin YK, et al. Amitriptyline modulation of Na(+) channels in rat dorsal root ganglion neurons. Eur J Pharmacol 2000; 401: 297–305PubMedCrossRef
23.
Wang GK, Russell C, Wang SY. State-dependent block of voltage-gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 2004; 110: 166–74PubMedCrossRef
24.
Pancrazio JJ, Kamatchi GL, Roscoe AK, et al. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 284: 208–14PubMed
25.
Deffois A, Fage D, Carter C. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci Lett 1996; 220: 117–20PubMedCrossRef
26.
Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999; 291: 280–4PubMed
27.
Sudoh Y, Cahoon EE, Gerner P, et al. Tricyclic antidepressants as long-acting local anesthetics. Pain 2003; 103: 49–55PubMedCrossRef
28.
Apkarian AV, Bushneil MC, Treede RD, et al. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 2005; 9: 463–84PubMedCrossRef
29.
Neugebauer V, Li W, Bird GC, et al. The amygdala and persistent pain. Neuroscientist 2004; 10: 221–34PubMedCrossRef
30.
Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron 2007; 55: 377–91PubMedCrossRef
31.
Zhao MG, Ko SW, Wu LJ, et al. Enhanced presynaptic neuro-transmitter release in the anterior cingulate cortex of mice with chronic pain. J Neurosci 2006; 26: 8923–30PubMedCrossRef
32.
Zhuo M. Molecular mechanisms of pain in the anterior cingulate cortex. J Neurosci Res 2006; 84: 927–33PubMedCrossRef
33.
Baliki MN, Geha PY, Apkarian AV, et al. Beyond feeling: chronic pain hurts the brain, disrupting the default-mode network dynamics. J Neurosci 2008; 28: 1398–403PubMedCrossRef
34.
Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 2005; 6: 545–52PubMedCrossRef
35.
36.
Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 2002; 25: 319–25PubMedCrossRef
37.
Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol 1998; 124: 669–74PubMedCrossRef
38.
Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999; 273: 85–8PubMedCrossRef
39.
Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects: a possible opioid involvement in severe depression? J Mol Neurosci 2002; 18: 143–9PubMedCrossRef
40.
Lavoie PA, Beauchamp G, Elie R. Tricyclic antidepressants inhibit voltage-dependent calcium channels and Na(+)-Ca2+ exchange in rat brain cortex synaptosomes. Can J Physiol Pharmacol 1990; 68: 1414–8PubMedCrossRef
41.
Lavoie PA, Beauchamp G, Elie R. Atypical antidepressants inhibit depolarization-induced calcium uptake in rat hippocampus synaptosomes. Can J Physiol Pharmacol 1997; 75: 983–7PubMedCrossRef
42.
Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983; 306: 686–8PubMedCrossRef
43.
Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007; 10: 1361–8PubMedCrossRef
44.
Wen YR, Suter MR, Kawasaki Y, et al. Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model. Anesthesiology 2007; 107: 312–21PubMedCrossRef
45.
Zhuang ZY, Wen YR, Zhang DR, et al. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 2006; 26: 3551–60PubMedCrossRef
46.
Scholz J, Broom DC, Youn DH, et al. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 2005; 25: 7317–23PubMedCrossRef
47.
Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology 1995; 83: 1046–54PubMedCrossRef
48.
Jensen TS, Gottrup H, Sindrup SH, et al. The clinical picture of neuropathic pain. Eur J Pharmacol 2001; 429: 1–11PubMedCrossRef
49.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; (4): CD005454
50.
Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13: 327–31PubMedCrossRef
51.
Cardenas DD, Warms CA, Turner JA, et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 2002; 96: 365–73PubMedCrossRef
52.
Feinmann C, Harris M, Cawley R. Psychogenic facial pain: presentation and treatment. BMJ (Clin Res Ed) 1984; 288: 436–8CrossRef
53.
Gomez-Perez FJ, Rull JA, Dies H, et al. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy: a double-blind cross-over study. Pain 1985; 23: 395–400PubMedCrossRef
54.
Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000; 16: 188–92PubMedCrossRef
55.
Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 51: 1682–8
56.
Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990; 47: 305–12PubMedCrossRef
57.
Kvinesdal B, Molin J, Froland A, et al. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251: 1727–30PubMedCrossRef
58.
Lampl C, Yazdi K, Roper C. Amitriptyline in the prophylaxis of central poststroke pain: preliminary results of 39 patients in a placebo-controlled, long-term study. Stroke 2002; 33: 3030–2PubMedCrossRef
59.
Leijon G, Boivie J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain 1989; 36: 27–36PubMedCrossRef
60.
Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589–96PubMedCrossRef
61.
Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427–32PubMedCrossRef
62.
Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3–9PubMedCrossRef
63.
McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol 2000; 49: 574–9PubMedCrossRef
64.
Mercadante S, Arcuri E, Tirelli W, et al. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori 2002; 88: 239–42PubMed
65.
Panerai AE, Monza G, Movilia P, et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 1990; 82: 34–8PubMedCrossRef
66.
Pilowsky I, Hallett EC, Bassett DL, et al. A controlled study of amitriptyline in the treatment of chronic pain. Pain 1982; 14: 169–79PubMedCrossRef
67.
Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59: 1015–21PubMedCrossRef
68.
Robinson LR, Czerniecki JM, Ehde DM, et al. Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study. Arch Phys Med Rehabil 2004; 85: 1–6PubMed
69.
Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110: 697–706PubMedCrossRef
70.
Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998; 280: 1590–5
71.
Sindrup SH, Ejlertsen B, Froland A, et al. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989; 37: 151–3PubMedCrossRef
72.
Sindrup SH, Gram LF, Skjold T, et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms: a double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683–91PubMedCrossRef
73.
Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135–44PubMedCrossRef
74.
Sindrup SH, Tuxen C, Gram LF, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251–5PubMedCrossRef
75.
Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60: 1284–9PubMedCrossRef
76.
77.
Vrethem M, Boivie J, Arnqvist H, et al. A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997; 13: 313–23PubMedCrossRef
78.
Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671–3PubMedCrossRef
79.
Carasso RL, Yehuda S, Streifler M. Clomipramine and amitriptyline in the treatment of severe pain. Int J Neurosci 1979; 9: 191–4PubMedCrossRef
80.
Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250–6PubMedCrossRef
81.
Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. Pain 1992; 48: 29–36PubMedCrossRef
82.
Ventafridda V, Bonezzi C, Caraceni A, et al. Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone. Ital J Neurol Sci 1987; 8: 579–87PubMedCrossRef
83.
Gobel H, Stadler T. Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine [in French]. Drugs 1997; 53 Suppl. 2: 34–9
84.
Langohr HD, Stohr M, Petruch F. An open and double-blind cross-over study on the efficacy of clomipramine (Anafranil) in patients with painful mono- and polyneuropathies. Eur Neurol 1982; 21: 309–17PubMedCrossRef
85.
Biesbroeck R, Bril V, Hollander P, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 1995; 12: 111–20PubMed
86.
Hampf G, Bowsher D, Nurmikko T. Distigmine and amitriptyline in the treatment of chronic pain. Anesth Prog 1989; 36: 58–62PubMed
87.
Dallocchio C, Buffa C, Mazzarello P, et al. Gabapentin vs amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20: 280–5PubMedCrossRef
88.
Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931–7PubMedCrossRef
89.
Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51: 1166–71PubMedCrossRef
90.
Gerson GR, Jones RB, Luscombe DK. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia. Postgrad Med J 1977; 53 Suppl. 4: 104–9
91.
Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996; 64: 293–302PubMedCrossRef
92.
Gomez-Perez FJ, Choza R, Rios JM, et al. Nortriptyline-fluphenazine vs carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996; 27: 525–9PubMed
93.
Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547–52PubMedCrossRef
94.
Maina G, Vitalucci A, Gandolfo S, et al. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002; 63: 38–43PubMedCrossRef
95.
Ciaramella A, Grosso S, Poli P. Fluoxetine versus fluvoxamine for treatment of chronic pain [in Italian]. Minerva Anestesiol 2000; 66: 55–61PubMed
96.
Forssell H, Tasmuth T, Tenovuo O, et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004; 18: 131–7PubMed
97.
Reuben SS, Makari-Judson G, Lurie SD. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manage 2004; 27: 133–9PubMedCrossRef
98.
Yucel A, Ozyalcin S, Koknel TG, et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain 2005; 9: 407–16PubMedCrossRef
99.
Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002; 6: 17–24PubMedCrossRef
100.
Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109–18PubMedCrossRef
101.
Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346–56PubMedCrossRef
102.
Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411–20PubMedCrossRef
103.
Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007; 29 Suppl.: 2536–46PubMedCrossRef
104.
Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289–305PubMedCrossRef
105.
Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13: 1153–69PubMedCrossRef
106.
Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002; 98: 195–203PubMedCrossRef
107.
Kautio AL, Haanpaa M, Saarto T, et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008; 35: 31–9PubMedCrossRef
108.
Tomkins GE, Jackson JL, O’Malley PG, et al. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 2001; 111: 54–63PubMedCrossRef
109.
Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1964; I: 1236–9CrossRef
110.
Diamond S, Baltes BJ. Chronic tension headache treated with amitriptyline: a double-blind study. Headache 1971; 11: 110–6PubMedCrossRef
111.
Jacobs H. A trial of opipramol in the treatment of migraine. J Neurol Neurosurg Psychiatry 1972; 35: 500–4PubMedCrossRef
112.
Okasha A, Ghaleb HA, Sadek A. A double blind trial for the clinical management of psychogenic headache. Br J Psychiatry 1973; 122: 181–3PubMedCrossRef
113.
114.
Morland TJ, Storli OV, Mogstad TE. Doxepin in the prophylactic treatment of mixed ‘vascular’ and tension headache. Headache 1979; 19: 382–3PubMedCrossRef
115.
Noone JF. Clomipramine in the prevention of migraine. J Int Med Res 1980; 8 Suppl. 3: 49–52
116.
Fogelholm R, Murros K. Maprotiline in chronic tension headache: a double-blind cross-over study. Headache 1985; 25: 273–5PubMedCrossRef
117.
Langemark M, Loldrup D, Bech P, et al. Clomipramine and mianserin in the treatment of chronic tension headache: a double-blind, controlled study. Headache 1990; 30: 118–21PubMedCrossRef
118.
Gobel H, Hamouz V, Hansen C, et al. Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not alter pericranial muscle activity readings. Pain 1994; 59: 241–9PubMedCrossRef
119.
Pfaffenrath V, Diener HC, Isler H, et al. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension-type headache: a multi-centre controlled study. Cephalalgia 1994; 14: 149–55PubMedCrossRef
120.
Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996; 61: 285–90PubMedCrossRef
121.
Ziegler DK, Hurwitz A, Hassanein RS, et al. Migraine prophylaxis: a comparison of propranolol and amitriptyline. Arch Neurol 1987; 44: 486–9PubMedCrossRef
122.
Indaco A, Carrieri PB. Amitriptyline in the treatment of headache in patients with Parkinson’s disease: a double-blind placebo-controlled study. Neurology 1988; 38: 1720–2PubMedCrossRef
123.
Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973; 36: 684–90PubMedCrossRef
124.
Mathew NT. Prophylaxis of migraine and mixed headache: a randomized controlled study. Headache 1981; 21: 105–9PubMedCrossRef
125.
Langohr HD, Gerber WD, Koletzki E, et al. Clomipramine and metoprolol in migraine prophylaxis: a double-blind crossover study. Headache 1985; 25: 107–13PubMedCrossRef
126.
Lance JW, Anthony M. Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine. Med J Aust 1968; 1: 54–5PubMed
127.
Sjaastad O, Stensrud P. Appraisal of BC-105 in migraine prophylaxis. Acta Neurol Scand 1969; 45: 594–600PubMedCrossRef
128.
Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): a double blind trial. N Z Med J 1971; 73: 5–9PubMed
129.
Hughes RC, Foster JB. BC 105 in the prophylaxis of migraine. Curr Ther Res Clin Exp 1971; 13: 63–8PubMed
130.
Ryan RE. BC-105 a new preparation for the interval treatment of migraine: a double blind evaluation compared with a placebo. Headache 1971; 11: 6–18PubMedCrossRef
131.
Carroll JD, Maclay WP. Pizotifen (BC 105) in migraine prophylaxis. Curr Med Res Opin 1975; 3: 68–71PubMedCrossRef
132.
Heathfield KW, Stone P, Crowder D. Pizotifen in the treatment of migraine. Practitioner 1977; 218: 428–30PubMed
133.
Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis, controlled multicenter trial in general practice. Headache 1977; 17: 109–12PubMedCrossRef
134.
Osterman PO. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. Acta Neurol Scand 1977; 56: 17–28PubMedCrossRef
135.
Kangasniemi P. Placebo, 1-isopropylnoradrenochrome-5-monosemicarbazono and pizotifen in migraine prophylaxis. Headache 1979; 19: 219–22PubMedCrossRef
136.
Denaro A, Martucci N, Ruggieri S, et al. Headache and nor-adrenergic involvement: the effects of alpha 2-stimulants and alpha 2-antagonists. Acta Psychiatr Scand Suppl 1985; 320: 20–5PubMedCrossRef
137.
Monro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. Acta Psychiatr Scand Suppl 1985; 320: 98–103PubMedCrossRef
138.
Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30: 710–5PubMedCrossRef
139.
Cleland PG, Barnes D, Elrington GM, et al. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol 1997; 38: 31–8PubMedCrossRef
140.
Bademosi O, Osuntokun BO. Pizotifen in the management of migraine. Practitioner 1978; 220: 325–7PubMed
141.
Zeeberg I, Orholm M, Nielsen JD, et al. Femoxetine in the prophylaxis of migraine: a randomised comparison with placebo. Acta Neurol Scand 1981; 64: 452–9PubMedCrossRef
142.
Sjaastad O. So-called “tension headache”. The response to a 5-HT uptake inhibitor: femoxetine. Cephalalgia 1983; 3: 53–60
143.
Orholm M, Honore PF, Zeeberg I. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. Acta Neurol Scand 1986; 74: 235–9PubMedCrossRef
144.
145.
Manna V, Bolino F, Di CL. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache 1994; 34: 44–9PubMedCrossRef
146.
Saper JR, Silberstein SD, Lake III AE, et al. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34: 497–502PubMedCrossRef
147.
148.
Sarchielli P, Mancini ML, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging 2006; 23: 461–89PubMedCrossRef
149.
Moja PL, Cusi C, Sterzi RR, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; (3): CD002919
150.
d’Amato CC, Pizza V, Marmolo T, et al. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39: 716–9PubMedCrossRef
151.
Steiner TJ, Ahmed F, Findley LJ, et al. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998; 18: 283–6PubMedCrossRef
152.
Landy S, McGinnis J, Curlin D, et al. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999; 39: 28–32PubMedCrossRef
153.
Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994; 34: 476–8PubMedCrossRef
154.
Oguzhanoglu A, Sahiner T, Kurt T, et al. Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches. Cephalalgia 1999; 19: 531–2PubMedCrossRef
155.
Walker Z, Walker RW, Robertson MM, et al. Antidepressant treatment of chronic tension-type headache: a comparison between fluoxetine and desipramine. Headache 1998; 38: 523–8PubMedCrossRef
156.
Langemark M, Bach FW, Jensen TS, et al. Decreased nociceptive flexion reflex threshold in chronic tension-type headache. Arch Neurol 1993; 50: 1061–4PubMedCrossRef
157.
Krymchantowski AV, Silva MT, Barbosa JS, et al. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002; 42: 510–4PubMedCrossRef
158.
Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62: 1706–11PubMedCrossRef
159.
Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107: 44–8PubMedCrossRef
160.
Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45: 144–52PubMedCrossRef
161.
Cassidy JD, Carroll LJ, Cote P. The Saskatchewan health and back pain survey: the prevalence of low back pain and related disability in Saskatchewan adults. Spine 1998; 23: 1860–6PubMedCrossRef
162.
Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med 2002; 162: 19–24PubMedCrossRef
163.
Staiger TO, Gaster B, Sullivan MD, et al. Systematic review of antidepressants in the treatment of chronic low back pain. Spine 2003; 28: 2540–5PubMedCrossRef
164.
Katz J, Pennella-Vaughan J, Hetzel RD, et al. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J Pain 2005; 6: 656–61PubMedCrossRef
165.
Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain. J Int Med Res 1976; 4: 28–40PubMed
166.
Alcoff J, Jones E, Rust P, et al. Controlled trial of imipramine for chronic low back pain. J Fam Pract 1982; 14: 841–6PubMed
167.
Ward N, Bokan JA, Phillips M, et al. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. J Clin Psychiatry 1984; 45: 54–9PubMed
168.
Hameroff SR, Weiss JL, Lerman JC, et al. Doxepin’s effects on chronic pain and depression: a controlled study. J Clin Psychiatry 1984; 45: 47–53PubMed
169.
Atkinson JH, Slater MA, Williams RA, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain 1998; 76: 287–96PubMedCrossRef
170.
Pheasant H, Bursk A, Goldfarb J, et al. Amitriptyline and chronic low-back pain: a randomized double-blind crossover study. Spine 1983; 8: 552–7PubMedCrossRef
171.
Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of nor-adrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999; 83: 137–45PubMedCrossRef
172.
Goodkin K, Gullion CM, Agras WS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. J Clin Psychopharmacol 1990; 10: 269–78PubMedCrossRef
173.
Dickens C, Jayson M, Sutton C, et al. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics 2000; 41: 490–9PubMedCrossRef
174.
Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147: 505–14PubMed
175.
Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72PubMedCrossRef
176.
Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19: 104–9PubMed
177.
Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992; 19: 846–50PubMed
178.
Arnold LM, Keck Jr PE, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000; 41: 104–13PubMedCrossRef
179.
O’Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000; 15: 659–66PubMedCrossRef
180.
Carette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis: a double-blind, placebo-controlled study. Arthritis Rheum 1986; 29: 655–9PubMedCrossRef
181.
Caruso I, Sarzi Puttini PC, Boccassini L, et al. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987; 15: 154–9PubMed
182.
Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis: a double-blind controlled study. Arthritis Rheum 1988; 31: 1535–42PubMedCrossRef
183.
Quimby LG, Gratwick GM, Whitney CD, et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl 1989; 19: 140–3PubMed
184.
Carette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995; 38: 1211–7PubMedCrossRef
185.
Reynolds WJ, Moldofsky H, Saskin P, et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991; 18: 452–4PubMed
186.
Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292: 2388–95PubMedCrossRef
187.
Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994; 37: 32–40
188.
Scudds RA, McCain GA, Rollman GB, et al. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl 1989; 19: 98–103PubMed
189.
Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998; 37: 1279–86PubMedCrossRef
190.
Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986; 29: 1371–7PubMedCrossRef
191.
Kempenaers C, Simenon G, Vander EM, et al. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology 1994; 30: 66–72PubMedCrossRef
192.
Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61: 445–9PubMedCrossRef
193.
Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23: 255–9PubMedCrossRef
194.
Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39: 1852–9PubMedCrossRef
195.
Tavoni A, Vitali C, Bombardiert S, et al. Evaluation of S-adenosylmethionine in primary fibromyalgia: a double-blind crossover study. Am J Med 1987; 83: 107–10PubMedCrossRef
196.
Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation. Scand J Rheumatol 1991; 20: 294–302PubMedCrossRef
197.
Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112: 191–7PubMedCrossRef
198.
Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32: 1975–85PubMed
199.
Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974–84PubMedCrossRef
200.
Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5–15PubMedCrossRef
201.
Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136: 432–44PubMedCrossRef
202.
Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol 2007; 19: 111–7PubMed
203.
Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001; 62 Suppl. 8: 38–45PubMed
204.
Jackson JL, O’Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65–72PubMedCrossRef
205.
Loldrup D, Langemark M, Hansen HJ, et al. Clomipramine and mianserin in chronic idiopathic pain syndrome: a placebo controlled study. Psychopharmacology (Berl) 1989; 99: 1–7CrossRef
206.
Myren J, Lovland B, Larssen SE, et al. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984; 19: 835–43PubMed
207.
Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 160–5PubMedCrossRef
208.
Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. Psychosomatics 1978; 19: 540–7PubMed
209.
Tripathi BM, Misra NP, Gupta AK. Evaluation of tricyclic compound (trimipramine) vis-a-vis placebo in irritable bowel syndrome (double blind randomised study). J Assoc Physicians India 1983; 31: 201–3PubMed
210.
Greenbaum DS, Mayle JE, Vanegeren LE, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987; 32: 257–66PubMedCrossRef
211.
Myren J, Groth H, Larssen SE, et al. The effect of trimipramine in patients with the irritable bowel syndrome: a double-blind study. Scand J Gastroenterol 1982; 17: 871–5PubMedCrossRef
212.
Steinhart MJ, Wong PY, Zarr ML. Therapeutic usefulness of amitriptyline in spastic colon syndrome. Int J Psychiatry Med 1981; 11: 45–57PubMedCrossRef
213.
Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13: 738–41PubMedCrossRef
214.
Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder: a double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996; 31: 318–25PubMedCrossRef
215.
Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; (2): CD003460
216.
Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219–28PubMedCrossRef
217.
Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004; 99: 914–20PubMedCrossRef
218.
Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095–103PubMedCrossRef
219.
220.
Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001; 93: 247–57PubMedCrossRef
221.
Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006; 7: 797–809PubMedCrossRef
222.
Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004; 9: 571–91PubMedCrossRef
223.
Pargeon KL, Hailey BJ. Barriers to effective cancer pain management: a review of the literature. J Pain Symptom Manage 1999; 18: 358–68PubMedCrossRef
224.
Sjogren P, Banning AM, Jensen NH, et al. Management of cancer pain in Denmark: a nationwide questionnaire survey. Pain 1996; 64: 519–25PubMedCrossRef
225.
McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain 2003; 106: 127–33PubMedCrossRef
226.
McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004; 111: 77–83PubMedCrossRef
227.
Von KM, Crane P, Lane M, et al. Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication. Pain 2005; 113: 331–9CrossRef
228.
Kirmayer LJ, Robbins JM, Dworkind M, et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993; 150: 734–41PubMed
229.
Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003; 60: 39–47PubMedCrossRef
230.
Husain MM, Rush AJ, Trivedi MH, et al. Pain in depression: STAR*D study findings. J Psychosom Res 2007; 63: 113–22PubMedCrossRef
231.
Hudson JI, Hudson MS, Pliner LF, et al. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 1985; 142: 441–6PubMed
232.
Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. Pain 2004; 107: 54–60PubMedCrossRef
233.
Patten SB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Disord 2001;63: 35–41PubMedCrossRef
234.
Magni G, Moreschi C, Rigatti-Luchini S, et al. Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain 1994; 56: 289–97PubMedCrossRef
235.
Larson SL, Clark MR, Eaton WW. Depressive disorder as a long-term antecedent risk factor for incident back pain: a 13-year follow-up study from the Baltimore Epidemiological Catchment Area sample. Psychol Med 2004; 34: 211–9PubMedCrossRef
236.
Pine DS, Cohen P, Brook J. The association between major depression and headache: results of a longitudinal epidemiologic study in youth. J Child Adolesc Psychopharmacol 1996; 6: 153–64PubMedCrossRef
237.
Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433–45PubMedCrossRef
238.
Lepine JP, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol 2004; 19 Suppl. 1: S3–7PubMedCrossRef
239.
Dersh J, Gatchel RJ, Polatin P, et al. Prevalence of psychiatric disorders in patients with chronic work-related musculoskeletal pain disability. J Occup Environ Med 2002; 44: 459–68PubMedCrossRef
240.
Burns JW, Johnson BJ, Mahoney N, et al. Cognitive and physical capacity process variables predict long-term outcome after treatment of chronic pain. J Consult Clin Psychol 1998; 66: 434–9PubMedCrossRef
241.
Lin EH, Katon W, Von KM, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. JAMA 2003; 290: 2428–9PubMedCrossRef
242.
Fishbain DA. The association of chronic pain and suicide. Semin Clin Neuropsychiatry 1999; 4: 221–7PubMed
243.
Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001; 26: 37–43PubMed
244.
Berney A, Nishikawa M, Benkelfat C, et al. An index of 5-HT synthesis changes during early antidepressant treatment: alpha-[HC]methyl-L-tryptophan PET study. Neurochem Int 2008; 52: 701–8PubMedCrossRef
245.
Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001; 26: 30–6PubMed
246.
Perrot S, Maheu E, Javier RM, et al. Guidelines for the use of antidepressants in painful rheumatic conditions. Eur J Pain 2006; 10: 185–92PubMedCrossRef
247.
Rintala DH, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1547–60PubMedCrossRef
248.
Colombo B, Annovazzi PO, Comi G. Therapy of primary headaches: the role of antidepressants. Neurol Sci 2004; 25 Suppl. 3: S171–5PubMedCrossRef
249.
Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 58–77PubMedCrossRef
250.
Chutka DS. Cardiovascular effects of the antidepressants: recognition and control. Geriatrics 1990; 45: 55–9, 62, 67PubMed
251.
252.
Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005; 39: 43–53PubMedCrossRef
253.
Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007; 68: 1707–16PubMedCrossRef
254.
Nieuwstraten C, Labiris NR, Holbrook A. Systematic overview of drug interactions with antidepressant medications. Can J Psychiatry 2006; 51: 300–16PubMed
255.
Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58: 291–7PubMedCrossRef
256.
Mayr BJ, Bonelli RM. Severe headache with venlafaxine withdrawal. Ann Pharmacother 2003; 37: 1145–6PubMedCrossRef
257.
Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther 2007; 82: 606–9PubMedCrossRef
258.
Kirchheiner J, Seeringer A. Clinical implications of pharmaco-genetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007; 1770: 489–94PubMedCrossRef
259.
Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004; 75: 386–93PubMedCrossRef
260.
McAlpine DE, O’Kane DJ, Black JL, et al. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc 2007; 82: 1065–8PubMedCrossRef
261.
Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007; 81: 899–902PubMedCrossRef
262.
Ereshefsky L, Jhee S, Grothe D. Antidepressant drug-drug interaction profile update. Drugs R D 2005; 6: 323–36PubMedCrossRef
263.
Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401–9PubMedCrossRef
264.
Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005; 77: 312–23PubMedCrossRef
265.
Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007; 29 Suppl.: 2477–97PubMedCrossRef
Metadata
Title
Antidepressants for the Treatment of Chronic Pain
Authors
Bénédicte Verdu
Isabelle Decosterd
Thierry Buclin
Professor Friedrich Stiefel
Alexandre Berney
Publication date
01-12-2008
Publisher
Springer International Publishing
Published in
Drugs / Issue 18/2008
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/0003495-200868180-00007

Other articles of this Issue 18/2008

Drugs 18/2008 Go to the issue

Leading Article

Current and Emerging Management Options for Hereditary Angioedema in the US

Adis Drug Evaluation

Teriparatide

Current Opinion

Therapeutic Potential of Vaccines in the Management of Hypertension

Adis Drug Profile

Tigecycline

Adis Drug Evaluation

Ibandronate

Review Article

Strategies to Improve Adherence and Outcomes in Patients with Ulcerative Colitis